Nektar Therapeutics (NKTR) Misses Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. BBIO
7. SPY
8. RCKT
9. NVDA
10. CRBU

Go back to Nektar Therapeutics (NKTR) Misses Q2 EPS by 3c

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2016

August 3, 2016 4:15 PM EDT

SAN FRANCISCO, Aug. 3, 2016 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2016.

Cash and investments in marketable securities at June 30, 2016 were $274.9 million as compared to $308.9 million at December 31, 2015. This balance includes the $28.0 million payment received from AstraZeneca in April of 2016 for the sublicense of MOVENTIG® (naloxegol) to ProStraken in Europe. The balance does not include the $20 million upfront payment for the licensing of European rights for ONZEALD to Daiichi Sankyo Europe, which occurred in Q2 2016.   

"We continue to execute... More